Ma L, Cui S J, Han C W, Jiang Y W, Zhao M M, Liu Y, Chen L J, Cao Y T
Department of Clinical Laboratory, China-Japan Friendship Hospital, Beijing 100029, China.
Beijing Center for Diseases Prevention and Control & Beijing Research Center for Prevention Medicine, Beijing 100013, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2021 Feb 6;55(2):219-225. doi: 10.3760/cma.j.cn112150-20201104-01334.
To evaluate the performance and application of a fast nucleic acid detection system for testing severe acute respiratory syndrome virus 2 (SARS-COV-2). Clinical samples were collected from February to July 2020 from Beijing Center for Diseases Prevention and Control and the Laboratory Department of China-Japan Friendship Hospital, to evaluate the sensitivity, specificity, anti-interference ability, precision and clinical sample coincidence rate of fast nucleic acid detection system for SARS-CoV-2. The analytical sensitivity was determined by a dilution series of 20 replications for each concentration. Analytical specificity study was performed by testing organisms whose infection produces symptoms similar to those observed at the onset of corona virus disease 2019 (COVID-19), and of the normal or pathogenic microflora that may be present in specimens collected. Potential interference substances were evaluated with different concentration in the interference study. Precision study was conducted by estimating intra-and inter-batch variability. Clinical evaluation was performed by testing 230 oropharyngeal swab specimens and 95 sputum specimens in fast nucleic acid detection system, comparing with conventional real-time fluorescent quantitative PCR (RT-qPCR) and clinical diagnostic results. The analytical sensitivity of SARS-CoV-2 using fast nucleic acid detection system was 400 copies/ml. The result is negative for testing with the organisms that may likely in the circulating area or causing similar symptoms with SARS-CoV-2 and human nucleic acid, indicating that no cross reactivity with organisms. The results of precision test showed that the Coefficient of variation of Ct value of high, medium and low concentration samples was 1.90%-3.92%, and all of them were less than 5% in intra-and inter-batch testing. The results of the samples were still positive after adding the potential interfering substances, indicating that the possible interfering substances in the samples had no effect on the results. 98.46% and 97.85% diagnosis results of fast nucleic acid detection system were consistent with RT-qPCR and clinical diagnostic results, respectively. The fast nucleic acid detection system based on molecular parallel reaction can be used as a selection method for SARS-CoV-2 testing.
评估一种快速核酸检测系统在检测严重急性呼吸综合征冠状病毒2(SARS-CoV-2)方面的性能及应用。2020年2月至7月从北京市疾病预防控制中心和中日友好医院检验科收集临床样本,以评估SARS-CoV-2快速核酸检测系统的灵敏度、特异性、抗干扰能力、精密度及临床样本符合率。通过对每个浓度进行20次重复的稀释系列来确定分析灵敏度。通过检测感染后产生与2019冠状病毒病(COVID-19)发病时观察到的症状相似症状的生物体,以及检测采集标本中可能存在的正常或致病微生物群来进行分析特异性研究。在干扰研究中用不同浓度评估潜在干扰物质。通过估计批内和批间变异性进行精密度研究。通过在快速核酸检测系统中检测230份口咽拭子标本和95份痰液标本,并与传统实时荧光定量PCR(RT-qPCR)及临床诊断结果进行比较来进行临床评估。使用快速核酸检测系统检测SARS-CoV-2的分析灵敏度为400拷贝/ml。对可能在流行区域或引起与SARS-CoV-2及人类核酸相似症状的生物体检测结果为阴性,表明与生物体无交叉反应。精密度测试结果显示,高、中、低浓度样本Ct值的变异系数为1.90%-3.92%,批内和批间检测均小于5%。加入潜在干扰物质后样本结果仍为阳性,表明样本中可能的干扰物质对结果无影响。快速核酸检测系统的诊断结果与RT-qPCR及临床诊断结果的一致性分别为98.46%和97.85%。基于分子平行反应的快速核酸检测系统可作为SARS-CoV-2检测的一种选择方法。